NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- RYAH Group (“RYAH” or the “Company”), an A.I., big data and IoT device company focused on plant-based medicine dosing and analytics, today announced that it was granted a patent to utilize artificial intelligence for the analysis of medical cannabis data.
With U.S. Patent # 10,296,714, “Method and system for medical cannabinoid treatment and product selection,” RYAH’s big data platform will now use Artificial Intelligence (AI) to better identify and understand correlations between plant strains and medical indications. RYAH is currently processing 37 medical indications across medical databases and clinical trials. Additionally, information collected from RYAH’s dose-measuring devices is stored in RYAH’s HIPAA compliant database and processed using A.I. to produce fact-based decisions. Medical professionals, marketers, dispensaries, and other medical cannabis stakeholders will be able employ this database for research purposes, as it will feature anonymous, real-time patients’ feedback and accurate data.
“This patent is another step in our long-term strategy to be a market leader in creating a beneficial, predictive, enterprise data analytics solution in the medical plant industry,” stated Gregory Wagner, CEO of RYAH. “We expect this patent to further validate our expanding IoT product suite and open future medical and business opportunities that allow professionals to make informed decisions from real time strain-related usage data. This patent ultimately confirms our dedication in using artificial intelligence and big data to potentially change lives”
Research suggests that the prescription / recommendation process for medical cannabis and related products needs to be more efficient and more informative. RYAH’s data platform will use the latest technology, including AI, to streamline recommendation and prescription decision making process for both medical professionals and consumers. It is believed that the database will become an attractive feature for a wide range of potential partners and collaborators, especially since the cannabis market is shifting to data driven decision making. RYAH also has plans to expand to use its AI, big-data platform and IoT solutions into the growing nutraceutical market.
About RYAH Medtech, Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for growers, dispensaries and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation and United States rules and regulation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company, execution of additional distribution agreements; and the results users may receive from using RYAH; are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Contact
invest@ryah.com
1.917.525.2697